These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26948134)

  • 1. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma.
    Goldman KE; White EC; Rao AR; Kaptein JS; Lien WW
    Pract Radiat Oncol; 2016; 6(5):e149-e154. PubMed ID: 26948134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of
    Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
    J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
    Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.
    Wangaryattawanich P; Branstetter BF; Hughes M; Clump DA; Heron DE; Rath TJ
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1884-1888. PubMed ID: 30166429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT in the evaluation of anal carcinoma.
    Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
    Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of fluorodeoxyglucose positron emission tomography/computed tomography and inguinal sentinel lymph node biopsy in patients with anal cancer.
    De Nardi P; Guarneri G; Canevari C; Tamburini A; Slim N; Passoni P; Rosati R
    Colorectal Dis; 2019 Sep; 21(9):1017-1024. PubMed ID: 31077550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of positron emission tomography-computed tomography in the management of anal cancer.
    Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
    Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
    Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
    Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
    Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
    Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
    Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
    Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
    Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of
    Jung JH; Lee SW; Son SH; Kim CY; Lee CH; Jeong JH; Jeong SY; Ahn BC; Lee J
    Head Neck; 2017 Mar; 39(3):447-455. PubMed ID: 27726225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation.
    Yoon JW; Kim S; Kim SW; Kim YT; Kang WJ; Nam EJ
    Clin Nucl Med; 2016 Sep; 41(9):677-82. PubMed ID: 27276204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva.
    Rao YJ; Hassanzadeh C; Chundury A; Hui C; Siegel BA; Dehdashti F; DeWees T; Mullen D; Powell MA; Mutch DG; Schwarz JK; Grigsby PW
    Radiother Oncol; 2017 Mar; 122(3):445-451. PubMed ID: 28063696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinoma.
    Frood R; Mercer J; Brown P; Appelt A; Mistry H; Kochhar R; Scarsbrook A
    Eur Radiol; 2024 May; 34(5):3194-3204. PubMed ID: 37924344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.